New Compstatin Peptides Containing N-Terminal Extensions and Non-Natural Amino Acids Exhibit Potent Complement Inhibition and Improved Solubility Characteristics

Compstatin peptides are complement inhibitors that bind and inhibit cleavage of complement C3. Peptide binding is enhanced by hydrophobic interactions; however, poor solubility promotes aggregation in aqueous environments. We have designed new compstatin peptides derived from the W4A9 sequence (Ac-ICVWQDWGAHRCT-NH2, cyclized between C2 and C12), based on structural, computational, and experimental studies. Furthermore, we developed and utilized a computational framework for the design of peptides containing non-natural amino acids. These new compstatin peptides contain polar N-terminal extensions and non-natural amino acid substitutions at positions 4 and 9. Peptides with α-modified non-natural alanine analogs at position 9, as well as peptides containing only N-terminal polar extensions, exhibited similar activity compared to W4A9, as quantified via ELISA, hemolytic, and cell-based assays, and showed improved solubility, as measured by UV absorbance and reverse-phase HPLC experiments. Because of their potency and solubility, these peptides are promising candidates for therapeutic development in numerous complement-mediated diseases.

[1]  John D Lambris,et al.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. , 2014, Blood.

[2]  L. Walensky,et al.  Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress , 2014, Journal of medicinal chemistry.

[3]  George A. Khoury,et al.  Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family , 2014, ACS synthetic biology.

[4]  George A. Khoury,et al.  Forcefield_PTM: Ab Initio Charge and AMBER Forcefield Parameters for Frequently Occurring Post-Translational Modifications. , 2013, Journal of chemical theory and computation.

[5]  Christodoulos A Floudas,et al.  Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures. , 2013, Experimental eye research.

[6]  Liang Tong,et al.  Computational design of an unnatural amino acid dependent metalloprotein with atomic level accuracy. , 2013, Journal of the American Chemical Society.

[7]  Christodoulos A Floudas,et al.  Protein WISDOM: a workbench for in silico de novo design of biomolecules. , 2013, Journal of visualized experiments : JoVE.

[8]  Andrew Watkins,et al.  Adding Diverse Noncanonical Backbones to Rosetta: Enabling Peptidomimetic Design , 2013, PloS one.

[9]  John D Lambris,et al.  Complement in Immune and Inflammatory Disorders: Therapeutic Interventions , 2013, The Journal of Immunology.

[10]  Hongjun Bai,et al.  New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. , 2013, Immunobiology.

[11]  John D Lambris,et al.  Peptide inhibitors of C 3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria Supplemental Methods , 2013 .

[12]  H. K. Fung,et al.  De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. , 2012, Journal of medicinal chemistry.

[13]  Christodoulos A Floudas,et al.  Molecular Dynamics in Drug Design: New Generations of Compstatin Analogs , 2012, Chemical biology & drug design.

[14]  N. Abbott,et al.  Dimerization of helical β-peptides in solution. , 2012, Biophysical journal.

[15]  Eun Jung Choi,et al.  Incorporation of Noncanonical Amino Acids into Rosetta and Use in Computational Protein-Peptide Interface Design , 2012, PloS one.

[16]  D. Bok,et al.  Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration , 2011, Proceedings of the National Academy of Sciences.

[17]  John D Lambris,et al.  Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. , 2011, ACS chemical biology.

[18]  H. K. Fung,et al.  Recent Advances in De Novo Protein Design , 2011 .

[19]  C. Floudas,et al.  A New Generation of Potent Complement Inhibitors of the Compstatin Family , 2011, Chemical biology & drug design.

[20]  P. Rosenfeld,et al.  Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome Measures , 2011, Seminars in ophthalmology.

[21]  John D Lambris,et al.  Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. , 2011, Molecular immunology.

[22]  H. K. Fung,et al.  Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. , 2010, Biophysical journal.

[23]  Christodoulos A. Floudas,et al.  A network flow model for biclustering via optimal re-ordering of data matrices , 2010, J. Glob. Optim..

[24]  H. K. Fung,et al.  New compstatin variants through two de novo protein design frameworks. , 2010, Biophysical journal.

[25]  C A Floudas,et al.  Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases. , 2010, Current drug targets.

[26]  Matthieu Hamel,et al.  Journal of Medicinal Chemistry , 2010 .

[27]  J. Lambris,et al.  Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. , 2010, Advances in experimental medicine and biology.

[28]  John D Lambris,et al.  Recent developments in low molecular weight complement inhibitors. , 2009, Molecular immunology.

[29]  John D Lambris,et al.  Structure‐kinetic relationship analysis of the therapeutic complement inhibitor compstatin , 2009, Journal of molecular recognition : JMR.

[30]  Davy Guillarme,et al.  Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution , 2009, Analytical and bioanalytical chemistry.

[31]  Christodoulos A. Floudas,et al.  Biclustering via optimal re-ordering of data matrices in systems biology: rigorous methods and comparative studies , 2008, BMC Bioinformatics.

[32]  C A Floudas,et al.  Distance dependent centroid to centroid force fields using high resolution decoys , 2008, Proteins.

[33]  D. Ricklin,et al.  Compstatin: a complement inhibitor on its way to clinical application. , 2008, Advances in experimental medicine and biology.

[34]  John D Lambris,et al.  Complement-targeted therapeutics , 2007, Nature Biotechnology.

[35]  John D Lambris,et al.  Structure of Compstatin in Complex with Complement Component C3c Reveals a New Mechanism of Complement Inhibition* , 2007, Journal of Biological Chemistry.

[36]  J. Pablo,et al.  Thermodynamic Stability of β-Peptide Helices and the Role of Cyclic Residues , 2006 .

[37]  John D Lambris,et al.  Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. , 2006, Journal of medicinal chemistry.

[38]  John D Lambris,et al.  Expression of compstatin in Escherichia coli: incorporation of unnatural amino acids enhances its activity. , 2006, Protein expression and purification.

[39]  Bruce Randall Donald,et al.  A Novel Ensemble-Based Scoring and Search Algorithm for Protein Redesign and Its Application to Modify the Substrate Specificity of the Gramicidin Synthetase A Phenylalanine Adenylation Enzyme , 2005, J. Comput. Biol..

[40]  Christodoulos A. Floudas,et al.  Structure-Based Integrative Computational and Experimental Approach for the Optimization of Drug Design , 2005, International Conference on Computational Science.

[41]  J. Lambris,et al.  Structural Biology of the Complement System , 2005 .

[42]  John D Lambris,et al.  Structure, Dynamics, Activity, and Function of Compstatin and Design of More Potent Analogues , 2005 .

[43]  Dimitrios Morikis,et al.  Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. , 2005, Journal of medicinal chemistry.

[44]  John D Lambris,et al.  Synthetic small-molecule complement inhibitors. , 2004, Current opinion in investigational drugs.

[45]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[46]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[47]  Dimitrios Morikis,et al.  Studies of Structure-Activity Relations of Complement Inhibitor Compstatin. , 2004, The Journal of Immunology.

[48]  Bruce Randall Donald,et al.  A novel ensemble-based scoring and search algorithm for protein redesign, and its application to modify the substrate specificity of the gramicidin synthetase A phenylalanine adenylation enzyme , 2004, RECOMB.

[49]  John L. Klepeis,et al.  Design of peptide analogues with improved activity using a novel de novo protein design approach , 2004 .

[50]  John D Lambris,et al.  Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. , 2004, Biochemical Society transactions.

[51]  Wilfred F van Gunsteren,et al.  Molecular dynamics simulations of peptides containing an unnatural amino acid: Dimerization, folding, and protein binding , 2003, Proteins.

[52]  David Baker,et al.  Protein Structure Prediction Using Rosetta , 2004, Numerical Computer Methods, Part D.

[53]  C. Floudas,et al.  De Novo Protein Design " An Interplay of Global Optimization , Mixed-Integer Optimization and Experiments , 2004 .

[54]  P. Güntert.  Automated NMR structure calculation with CYANA. , 2004, Methods in molecular biology.

[55]  Dimitrios Morikis,et al.  Studies of Structure-Activity Relations of Complement Inhibitor Compstatin 1 , 2003 .

[56]  Jeffrey J. Gray,et al.  Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. , 2003, Journal of molecular biology.

[57]  Christodoulos A Floudas,et al.  Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. , 2003, Journal of the American Chemical Society.

[58]  Wolfgang Amadens.  The Second of Two Parts , 2003 .

[59]  Dimitrios Morikis,et al.  The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR* 210 , 2002, The Journal of Biological Chemistry.

[60]  D. Baker,et al.  De novo determination of protein backbone structure from residual dipolar couplings using Rosetta. , 2002, Journal of the American Chemical Society.

[61]  John D Lambris,et al.  Structural aspects and design of low-molecular-mass complement inhibitors. , 2001, Biochemical Society transactions.

[62]  M. Walport,et al.  Complement. Second of two parts. , 2001, The New England journal of medicine.

[63]  X. Daura,et al.  Entropy calculations on a reversibly folding peptide: Changes in solute free energy cannot explain folding behavior , 2001, Proteins.

[64]  X. Daura,et al.  The beta-peptide hairpin in solution: conformational study of a beta-hexapeptide in methanol by NMR spectroscopy and MD simulation. , 2001, Journal of the American Chemical Society.

[65]  D. Baker,et al.  2.1 and 1.8 Å Average Cα RMSD Structure Predictions on Two Small Proteins, HP-36 and S15 , 2001 .

[66]  D. Baker,et al.  Native protein sequences are close to optimal for their structures. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Dimitrios Morikis,et al.  Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin1 , 2000, The Journal of Immunology.

[68]  D. Case,et al.  Modification of the Generalized Born Model Suitable for Macromolecules , 2000 .

[69]  John D Lambris,et al.  Complement Inhibitors Targeting C3, C4, and C5 , 2000 .

[70]  X. Daura,et al.  Folding–unfolding thermodynamics of a β‐heptapeptide from equilibrium simulations , 1999, Proteins.

[71]  Dimitrios Morikis,et al.  Solution structure of Compstatin, a potent complement inhibitor , 1998, Protein science : a publication of the Protein Society.

[72]  K. Wüthrich,et al.  Torsion angle dynamics for NMR structure calculation with the new program DYANA. , 1997, Journal of molecular biology.

[73]  Philip M. Dean,et al.  Three-dimensional hydrogen-bond geometry and probability information from a crystal survey , 1996, J. Comput. Aided Mol. Des..

[74]  John D Lambris,et al.  Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. , 1996, Journal of immunology.

[75]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[76]  J. Reed,et al.  Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. , 1992, Journal of molecular biology.

[77]  Atsunobu Ichikawa,et al.  Process Systems Engineering , 2022 .